1 / 10

Spinal Muscular Atrophy Market

Spinal muscular atrophy is a genetic disorder characterized<br>by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement.<br>

DelveInsight
Download Presentation

Spinal Muscular Atrophy Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spinal Muscular Atrophy (SMA) Market Insights, Epidemiology and Market Forecast- 2028

  2. Spinal Muscular Atrophy (SMA) Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. SMA is a motor neuron disease caused by Bi-allelic mutation of survival motor neuron gene 1 (SMN1). There are two identical genes SMN1 (telomeric copy) and SMN2 (centromeric copy) present at human chromosome 5q13. These genes are responsible for synthesizing survival motor neuron protein, which is necessary for the normal function of motor neurons that control our muscles. There are many types of spinal muscular atrophy (SMA Type 0, I, II, III and IV) that are caused by changes in the same genes. The types differ in age of onset and severity of muscle weakness; however, there is overlap between the types. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age. SMA is the most common genetic disease resulting in death in infancy and therapies that improve neuromuscular function as well as maintain lifelong general health of people living are a major priority and are an unmet clinical need. 01 05 02 04 03 • DelveInsight © 2019 | All rights reserved

  3. SMA Epidemiology Survival motor neuron gene 1 (SMN1) EU-5 Countries Prevalence SMN1 is considered the active gene for survival of motor neuron protein production, and more than 98% of patients with spinal muscular atrophy have an abnormality in both SMN1 genes, which can be caused by a deletion (95%) of exon 7 or other mutation. Among the EU5 countries, Germany had the highest Spinal Muscular Atrophy prevalent population with 1,643 cases in 2017 followed by UK and France. On the other hand, Spain had the lowest Spinal Muscular Atrophy prevalence with 468 cases in 2017. Total prevalent population US Prevalence Spinal Muscular Atrophy total prevalent population was 19,343 in 7 major markets (7MM)* in 2017. Spinal Muscular Atrophy total prevalent population was found to be 13,036 in the United States in 2017. *7MM includes:- United States; EU 5 (Germany, France, Spain, Italy, United Kingdom); Japan. • DelveInsight © 2019 | All rights reserved

  4. SMAMarket Outlook SMA Market Size Spinal Muscular Atrophy market size was 1,317 Million in seven major markets in 2017 and is increasing at a CAGR of 10.42% for the study period (2017-2028). SMA US Market Size Spinal Muscular Atrophy total US market size was USD 892.37 Million in 2017. SMA in 7MM* Spinal Muscular Atrophy diagnosed prevalent population in 7MM is expected to increase at a CAGR of 0.88% for the study period i.e. 2017-2028. SMA Prevalence Spinal Muscular Atrophy total prevalence in the US is expected to increase at a CAGR of 0.77%. *7MM includes:- United States; EU 5 (Germany, France, Spain, Italy, United Kingdom); Japan. • DelveInsight © 2019 | All rights reserved

  5. SMA Emerging Drugs and Companies Drug- RISDIPLAM Company- ROCHE Drug- AMIFAMPRIDINE PHOSPHATE Company- CATALYST PHARMACEUTICALS 2010 2011 2012 2013 2014 Drug- ZOLGENSMA Company- NOVARTIS Drug- RELDESEMTIV Company- ASTELLAS PHARMA • DelveInsight © 2019 | All rights reserved

  6. Complete Information For complete information on Spinal Muscular Atrophy Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  7. About DelveInsight MISSION ABOUT VISION To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved

  8. Service Offerings by DelveInsight 01 05 FORECASTING OPPORTUNITY ASSESSMENT 02 06 PIPELINE REPORT STORE 03 07 COMPETITIVE ANALYSIS CONSULTING 04 08 MARKET INTELLIGENCE PHARMDELVE • DelveInsight © 2019 | All rights reserved

  9. Contact Us blog/delveInsight/ info@delveinsight.com +91-11-4568 9769 twitter/delveInsight LinkedIn/delveInsight www.delveinsight.com • DelveInsight © 2019 | All rights reserved

  10. THANK YOU

More Related